⚠ Evidence warning: Clinical trials or other evidence do not support the claim, described by integrative practitioners, that combining topical lemon balm, oral lemon balm, L-lysine, vitamin D, lip sunscreen and a standby oral antiviral controls recurrent cold sores for most people without daily prescription suppressive therapy. This page keeps it as a report of what people, websites or other media say.

Lemon Balm Antiviral & HSV Cold Sores

Lemon balm has one well-documented antiviral indication: topical treatment of recurrent herpes labialis (cold sores) caused by herpes simplex virus type 1 (HSV-1). The clinical studies are a 1994 paper by Reinhold Wölbling and Klaus Leonhardt in Germany (Phytomedicine), which reported an open multicentre study of 115 patients and a placebo-controlled double-blind study of 116 patients, and a 1999 single-centre double-blind trial of 66 patients by Koytchev and colleagues, all testing a cream made with a dried lemon balm leaf extract (in the 1999 trial, a standardized lemon balm cream containing 1% extract). The 1999 trial found lower symptom scores than placebo on day 2 of treatment; its authors also described a shorter healing period, less spreading of the infection, and some indication of longer gaps between outbreaks. The mechanism is polyphenol antiviral activity — rosmarinic acid and condensed tannins in lemon balm extract directly bind glycoproteins on the HSV envelope, blocking the attachment-and-entry step before the virus can establish intracellular infection. Topical lemon balm cream is used for mild recurrent cold sores, particularly by people who want a non-prescription option, but it does not replace systemic antivirals (acyclovir, valacyclovir, famciclovir) for severe outbreaks, immunocompromised patients, or HSV in anatomically sensitive locations.


Table of Contents

  1. HSV-1, Cold Sores, and the Recurrent Outbreak Pattern
  2. The Wölbling 1994 Studies
  3. The 1999 Double-Blind Trial and the 2025 Systematic Review
  4. The Polyphenol Antiviral Mechanism
  5. Rosmarinic Acid and HSV Attachment Blockade
  6. Lemon Balm Cream vs Topical Acyclovir Cream
  7. Lemon Balm Cream vs Oral Antivirals (Valacyclovir)
  8. Lemon Balm with Lysine and Other Adjuncts
  9. HSV-2 Genital Herpes — What We Know and Don't
  10. Beyond HSV: Other Enveloped Viruses
  11. How the Cream and Antivirals Are Used
  12. Cautions and Drug Interactions
  13. Key Research Papers
  14. Connections
  15. Featured Videos

HSV-1, Cold Sores, and the Recurrent Outbreak Pattern

Herpes simplex virus type 1 (HSV-1) is one of the most prevalent human pathogens — approximately 67% of the global population under 50 has serologic evidence of HSV-1 infection. Primary infection usually occurs in childhood through oral-oral contact and is often asymptomatic. After primary infection the virus establishes lifelong latency in the trigeminal ganglion, periodically reactivating and traveling down the trigeminal nerve to the lip and perioral skin, where it produces the characteristic vesicular eruption known as a cold sore or fever blister.

The recurrent outbreak pattern is highly individual. Some HSV-1-seropositive individuals never have a clinical outbreak. Others have one or two per year. A smaller fraction has frequent recurrences (six or more per year) that may warrant chronic suppressive antiviral therapy. Common reactivation triggers include:

The natural history of a typical cold sore outbreak follows a predictable arc: prodromal tingling and itching at the site (12-24 hours), erythema and swelling (day 1), vesicle formation (day 2), ulceration as vesicles rupture (day 3-4), crusting (day 5-7), and resolution with no scarring (day 8-12). Topical antivirals work best when started at the prodromal tingling stage, before the vesicles form; once the vesicles are open the treatment window has largely passed. This is the central practical fact that determines what any topical treatment can realistically accomplish.

Back to Table of Contents

The Wölbling 1994 Studies

The foundational clinical work on topical lemon balm cream for herpes simplex was published by Reinhold H. Wölbling and Klaus Leonhardt in 1994 in Phytomedicine. It tested a cream made with a specially prepared dried extract of Melissa officinalis leaves in patients with herpes simplex infections.

The paper reported two separate studies: first an open (uncontrolled) multicentre study of 115 patients, then a placebo-controlled, double-blind study of 116 patients. The authors concluded that the two studies supported, in patients, the antiviral activity the extract had shown against herpes simplex in the laboratory, and that treatment was most effective when it was started in the very early stages of the infection. The published summary does not give the size of the effect, such as the number of days of healing saved.

A standardized lemon balm cream based on this kind of extract is sold over the counter in Germany and several other European markets as a non-prescription topical for recurrent herpes labialis.

Back to Table of Contents

The 1999 Double-Blind Trial and the 2025 Systematic Review

The second placebo-controlled trial was published by Koytchev, Alken and Dundarov in 1999, also in Phytomedicine. It enrolled 66 patients at one centre, all with a history of recurrent herpes labialis (at least four episodes a year): 34 received a cream containing 1% of a dried lemon balm leaf extract (70:1) and 32 received a placebo cream. The cream was applied to the affected area four times daily for five days.

The main measure was a combined symptom score (complaints, size of the affected area and blisters) on day 2 of treatment, when cold-sore complaints are usually at their worst. The lemon balm group scored significantly better: 4.03 ± 0.33 versus 4.94 ± 0.40 for placebo (mean ± standard error). The authors also wrote that “some indication exists” that the gaps between outbreaks might be longer with the cream.

A 2025 systematic review of herbal creams for cold sores (Anheyer and colleagues) found 7 randomized controlled trials with 1,250 patients in total, covering lemon balm, olive leaf extract, propolis and a combined sage-rhubarb cream. Lemon balm preparations consistently reduced pain and swelling, and some studies also reported significantly smaller lesions than with placebo or acyclovir. The reviewers judged 2 of the 7 trials to be at low risk of bias and 5 to raise some concerns, noted that the total number of patients was small, and found side effects across all the studies minimal or absent.

Together with the 1994 studies, the 1999 trial is the main clinical evidence for topical lemon balm in recurrent HSV-1 cold sores.

Back to Table of Contents

The Polyphenol Antiviral Mechanism

The antiviral mechanism of lemon balm extract is fundamentally different from prescription antivirals like acyclovir. Acyclovir is a nucleoside analog that is phosphorylated by the HSV thymidine kinase, then incorporated into the viral DNA being synthesized by HSV DNA polymerase, where it terminates the growing DNA chain. Acyclovir is therefore specifically active inside HSV-infected cells, against actively replicating virus.

Lemon balm's polyphenols act at a completely different step — before the virus enters the host cell. The HSV envelope is studded with glycoproteins (gB, gC, gD, gH, gL) that mediate the multi-step attachment and fusion process by which HSV enters host cells. Initial attachment uses gB and gC binding to heparan sulfate proteoglycans on the host cell surface; subsequent receptor engagement uses gD binding to nectin-1 or herpesvirus entry mediator (HVEM); and final fusion of the viral envelope with the host plasma membrane uses gH/gL.

Polyphenols, particularly the larger ones with multiple phenolic hydroxyl groups, bind non-specifically to glycoproteins through hydrogen bonding to glycan side chains and to amino acid residues. When lemon balm extract is applied to the skin where HSV is replicating, the polyphenols coat the surface of newly released virions, masking the glycoprotein binding sites and physically blocking the attachment-and-entry step on neighboring host cells.

The clinical translation: lemon balm extract does not stop viral replication inside already-infected cells (which acyclovir does), but it blocks the spread of newly produced virus to uninfected neighboring cells — which is what determines how big the lesion gets, how much pain it causes, and how long it takes to heal. Stopping the spread early in the outbreak is what reduces lesion size, pain, and healing time, exactly the endpoints Wölbling measured.

The mechanism also explains why lemon balm works topically but not orally for HSV. Oral lemon balm provides plasma rosmarinic acid concentrations far below what is achievable in the local skin compartment from topical application, and the cold-sore epithelium is not particularly perfused. Topical delivery puts the polyphenol exactly where it needs to be, at concentrations sufficient to coat the local viral pool.

Back to Table of Contents

Rosmarinic Acid and HSV Attachment Blockade

Among the lemon balm polyphenols, rosmarinic acid is the leading single contributor to the antiviral effect. In vitro studies have demonstrated that purified rosmarinic acid:

The activity is not exclusive to rosmarinic acid — condensed tannins, caffeic acid, and the volatile monoterpenes (citral specifically) all contribute additively in whole-extract testing. The whole-extract activity is consistently stronger than any single isolated constituent, suggesting that the synergistic combination is what makes the clinical lemon balm cream effective.

The Schnitzler 2008 paper in Phytomedicine specifically tested lemon balm essential oil against HSV-1 and HSV-2 in plaque-reduction assays on monkey kidney cells (a cell-culture study). Half of plaque formation was blocked at very high dilutions of the oil — 0.0004% for HSV-1 and 0.00008% for HSV-2. At concentrations that did not harm the cells, plaque formation fell by 98.8% for HSV-1 and 97.2% for HSV-2, and higher concentrations abolished infectivity nearly completely. The effect came from treating the virus with the oil before it infected the cells, not after the virus had entered them. The essential oil mechanism appears to involve direct disruption of the viral envelope by the monoterpenes, in addition to the polyphenol attachment-blockade mechanism in the aqueous/ethanolic extract.

Two later cell-culture studies by the same research group show where the water extract acts. When the extract was added to cells that were already infected with HSV-1, it had no antiviral effect. Mixed with free virus, it was strongly virucidal (it inactivated the virus) at concentrations as low as 1.5 µg/mL, while its single phenolic compounds — caffeic acid, p-coumaric acid and rosmarinic acid — needed about 100 times higher concentrations for similar results; the extract and rosmarinic acid also blocked the virus from attaching to cells (Astani 2012). Against two acyclovir-resistant HSV-1 strains taken from patients, the extract acted directly on free virus particles at 50% inhibitory concentrations (IC50) of 0.13 and 0.23 µg/mL, and it blocked entry of the virus into cells by 96%, compared with 80% for drug-sensitive virus (Astani 2014).

Back to Table of Contents

Lemon Balm Cream vs Topical Acyclovir Cream

Topical acyclovir cream (5%, sold in the US and many other countries) is the conventional non-prescription topical for HSV-1 cold sores in Europe (it requires prescription in the US). Compared to topical acyclovir, lemon balm 1% cream:

The choice often comes down to preference, since neither cream has been shown to be better than the other. For more aggressive outbreaks, clinical reviews describe oral antiviral therapy as the standard treatment, whichever topical is used.

Back to Table of Contents

Lemon Balm Cream vs Oral Antivirals (Valacyclovir)

Oral antiviral therapy is the clinical standard for moderate-to-severe HSV-1 outbreaks and for patients with frequent recurrences (six or more per year). The three U.S. Food and Drug Administration-approved oral antivirals for HSV are:

In the first of the two Spruance 2003 valacyclovir trials, the one-day course shortened the median cold-sore episode by 1.0 day compared with placebo (0.5 day for a two-day course; mean reductions 1.1 and 0.7 days), and time to healing and to the end of pain were also significantly shorter. The share of people in whom the cold sore was stopped from developing rose by 6.4% and 8.5% over placebo, differences that were not statistically significant; the second trial gave similar results. Clinical reviews describe oral antivirals as the standard treatment for:

Practitioners describe topical lemon balm cream as an option for:

The two are not mutually exclusive. Practitioners describe people with frequent severe cold sores using oral valacyclovir for systemic antiviral effect plus topical lemon balm for local symptom relief and additional attachment blockade.

Back to Table of Contents

Lemon Balm with Lysine and Other Adjuncts

Several other non-prescription approaches are described for reducing HSV recurrences alongside topical lemon balm, with evidence of varying strength:

Integrative practitioners describe an approach that combines topical lemon balm for acute outbreaks, oral lemon balm for stress reduction, L-lysine and vitamin D for recurrence prevention, lip sunscreen for ultraviolet protection, and an oral antiviral on standby for severe outbreaks, and report that it covers most patients without chronic suppressive prescription therapy.

Back to Table of Contents

HSV-2 Genital Herpes — What We Know and Don't

HSV-2 is the second herpes simplex serotype, primarily associated with genital herpes infection. HSV-2 establishes latency in the sacral ganglia rather than the trigeminal ganglion, reactivating along sacral nerve roots to produce genital outbreaks. HSV-1 can also cause genital herpes when transmitted oral-genital, and increasingly does so in younger populations.

The clinical management of HSV-2 genital herpes differs from HSV-1 cold sores in several important ways:

Lemon balm's role in HSV-2 management is much more limited than in HSV-1. The published summary of the original Wölbling studies does not report separate results for genital herpes, and the formulation (creams designed for the lip) is not ideal for genital application. The in vitro antiviral activity is comparable between HSV-1 and HSV-2 (Schnitzler 2008), but the clinical trial evidence in actual genital herpes is sparse.

For most patients with HSV-2 genital herpes, clinical reviews describe oral antiviral therapy as the standard approach — episodic for infrequent outbreaks, chronic suppressive for frequent outbreaks or for partners who want to minimize transmission risk. Topical lemon balm is used by some as an adjunct for local symptom relief; it is not a substitute for systemic antiviral therapy in this indication.

Back to Table of Contents

Beyond HSV: Other Enveloped Viruses

The attachment-blockade mechanism of lemon balm polyphenols is in principle applicable to any enveloped virus with surface glycoproteins. In vitro testing has documented activity against several other clinically relevant viruses:

The general principle is that an enveloped virus is more susceptible to polyphenol antiviral activity than a non-enveloped virus (because the polyphenols target envelope glycoproteins). Non-enveloped viruses like rhinovirus (common cold), poliovirus, and norovirus are not meaningfully affected by lemon balm extract. In the 2008 HIV study, the extracts worked against several viruses that carry an envelope but not against a non-enveloped adenovirus.

The translation from in vitro activity to clinical benefit has not been adequately studied for any indication other than HSV-1 cold sores. Claims of lemon balm efficacy against other viral infections rest on laboratory data — the in vitro data are interesting and mechanistically supportive, but in vivo trials demonstrating clinical benefit do not exist outside the HSV-1 indication.

Back to Table of Contents

How the Cream and Antivirals Are Used

What the trials used, what the valacyclovir label states, and what practitioners describe for adults with a normal immune system and recurrent HSV-1 cold sores:

Back to Table of Contents

Cautions and Drug Interactions

Back to Table of Contents

Key Research Papers

  1. Wölbling RH, Leonhardt K (1994). Local therapy of herpes simplex with dried extract from Melissa officinalis. Phytomedicine. — PubMed PMID: 23195812
  2. Koytchev R, Alken RG, Dundarov S (1999). Balm mint extract (Lo-701) for topical treatment of recurring herpes labialis. Phytomedicine. — PubMed PMID: 10589440
  3. Schnitzler P, Schuhmacher A, Astani A, Reichling J (2008). Melissa officinalis oil affects infectivity of enveloped herpesviruses. Phytomedicine. — PubMed PMID: 18693101
  4. Astani A, Reichling J, Schnitzler P (2012). Melissa officinalis extract inhibits attachment of herpes simplex virus in vitro. Chemotherapy. — PubMed PMID: 22377592
  5. Mazzanti G, Battinelli L, Pompeo C, Serrilli AM, Rossi R, Sauzullo I, et al. (2008). Inhibitory activity of Melissa officinalis L. extract on herpes simplex virus type 2 replication. Natural Product Research. — PubMed PMID: 19023806
  6. Astani A, Navid MH, Schnitzler P (2014). Attachment and penetration of acyclovir-resistant herpes simplex virus are inhibited by Melissa officinalis extract. Phytotherapy Research. — PubMed PMID: 24817544
  7. Allahverdiyev A, Duran N, Ozguven M, Koltas S (2004). Antiviral activity of the volatile oils of Melissa officinalis L. against herpes simplex virus type-2. Phytomedicine. — PubMed PMID: 15636181
  8. Reichling J, Schnitzler P, Suschke U, Saller R (2009). Essential oils of aromatic plants with antibacterial, antifungal, antiviral, and cytotoxic properties — an overview. Forschende Komplementärmedizin. — PubMed PMID: 19420953
  9. Spruance SL, Jones TM, Blatter MM, Vargas-Cortes M, Barber J, Hill J, et al. (2003). High-dose, short-duration, early valacyclovir therapy for episodic treatment of cold sores. Antimicrobial Agents and Chemotherapy. — PubMed PMID: 12604544
  10. Worrall G (2009). Herpes labialis. BMJ Clinical Evidence. — PubMed PMID: 21726482
  11. Cernik C, Gallina K, Brodell RT (2008). The treatment of herpes simplex infections: an evidence-based review. Archives of Internal Medicine. — PubMed PMID: 18541820
  12. Shakeri A, Sahebkar A, Javadi B (2016). Melissa officinalis L. - A review of its traditional uses, phytochemistry and pharmacology. Journal of Ethnopharmacology. — PubMed PMID: 27167460
  13. Anheyer M, Cramer H, Ostermann T, Längler A, Anheyer D (2025). Herbal medicine for treating herpes labialis: a systematic review. Journal of Integrative and Complementary Medicine. — PubMed PMID: 40526027
  14. Geuenich S, Goffinet C, Venzke S, Nolkemper S, Baumann I, Plinkert P, Reichling J, Keppler OT (2008). Aqueous extracts from peppermint, sage and lemon balm leaves display potent anti-HIV-1 activity by increasing the virion density. Retrovirology. — PubMed PMID: 18355409

PubMed Topic Searches

  1. PubMed: Melissa HSV topical
  2. PubMed: Lemon balm cold sore cream
  3. PubMed: Rosmarinic acid HSV
  4. PubMed: Acyclovir cold sores
  5. PubMed: L-lysine HSV recurrence
  6. PubMed: Polyphenol antiviral mechanism
  7. PubMed: HSV-1 recurrence triggers

Back to Table of Contents

Connections

Back to Table of Contents